| Quarterly Statement of Operations and Other Comprehensive Loss |
24. Quarterly Statement of Operations and Other Comprehensive Loss (Unaudited)
The following table sets forth our quarterly Consolidated Statement of Operations and Other Comprehensive Loss (unaudited) data through the years ended December 31, 2022 and 2021:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Q1 2021 |
|
Q2 2021 |
|
Q3 2021 |
|
Q4 2021 |
|
Q1 2022 |
|
Q2 2022 |
|
Q3 2022 |
|
Q4 2022 |
|
$’000 |
|
$’000 |
|
$’000 |
|
$’000 |
|
$’000 |
|
$’000 |
|
$’000 |
|
$’000 |
| Revenue |
71,293 |
|
|
57,478 |
|
|
74,462 |
|
|
117,594 |
|
|
266,446 |
|
|
265,362 |
|
|
288,898 |
|
|
288,963 |
|
| Claims expense |
(23,917) |
|
|
(40,384) |
|
|
(51,298) |
|
|
(104,026) |
|
|
(247,552) |
|
|
(238,764) |
|
|
(264,283) |
|
|
(266,404) |
|
| Clinical care delivery expense |
(11,823) |
|
|
(16,013) |
|
|
(17,038) |
|
|
(24,957) |
|
|
(23,927) |
|
|
(21,649) |
|
|
(18,505) |
|
|
(16,543) |
|
| Platform & application expenses |
(4,718) |
|
|
(12,472) |
|
|
(4,852) |
|
|
(10,681) |
|
|
(13,748) |
|
|
(6,567) |
|
|
(5,074) |
|
|
(4,508) |
|
| Research & development expenses |
(16,246) |
|
|
(12,667) |
|
|
(25,195) |
|
|
(14,365) |
|
|
(17,314) |
|
|
(27,577) |
|
|
(23,008) |
|
|
(11,256) |
|
| Sales, general & administrative expenses |
(30,986) |
|
|
(43,753) |
|
|
(39,257) |
|
|
(73,176) |
|
|
(55,649) |
|
|
(64,503) |
|
|
(54,474) |
|
|
(53,311) |
|
| Impairment expense |
—
|
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
(24,820) |
|
|
(647) |
|
|
(38,599) |
|
| Depreciation and amortization expenses |
(713) |
|
|
(1,310) |
|
|
(2,659) |
|
|
(4,503) |
|
|
(3,078) |
|
|
(3,906) |
|
|
(2,456) |
|
|
(2,610) |
|
| Premium deficiency reserve (expense) / income |
(1,179) |
|
|
(25) |
|
|
2,870 |
|
|
(48,199) |
|
|
(6,868) |
|
|
9,123 |
|
|
21,518 |
|
|
7,538 |
|
| Loss from operations |
(18,289) |
|
|
(69,146) |
|
|
(62,967) |
|
|
(162,313) |
|
|
(101,690) |
|
|
(113,301) |
|
|
(58,031) |
|
|
(96,730) |
|
| Interest expense |
(1,083) |
|
|
(1,309) |
|
|
(1,684) |
|
|
(8,971) |
|
|
(5,982) |
|
|
(9,192) |
|
|
(8,255) |
|
|
(9,307) |
|
| Interest income |
14 |
|
|
14 |
|
|
2 |
|
|
295 |
|
|
255 |
|
|
128 |
|
|
284 |
|
|
374 |
|
| Loss on settlement of warrants |
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
(2,375) |
|
|
(22) |
|
|
— |
|
| Gain / (loss) on fair value remeasurement |
— |
|
|
— |
|
|
— |
|
|
239,195 |
|
|
78,773 |
|
|
99,957 |
|
|
11,249 |
|
|
2,770 |
|
| Exchange (loss) / gain |
(573) |
|
|
482 |
|
|
(396) |
|
|
1,270 |
|
|
(447) |
|
|
(7,350) |
|
|
(4,848) |
|
|
2,225 |
|
| Gain on sale of subsidiary |
3,917 |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
| Share of net loss on equity method investments |
(455) |
|
|
(821) |
|
|
(1,017) |
|
|
(1,046) |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
| Net loss before taxation |
(16,469) |
|
|
(70,780) |
|
|
(66,062) |
|
|
68,430 |
|
|
(29,091) |
|
|
(32,133) |
|
|
(59,623) |
|
|
(100,668) |
|
| Tax (provision) / benefit |
(8) |
|
|
2,501 |
|
|
(7) |
|
|
(1,043) |
|
|
(9) |
|
|
(199) |
|
|
(280) |
|
|
554 |
|
| Net loss |
(16,477) |
|
|
(68,279) |
|
|
(66,069) |
|
|
67,387
|
|
|
(29,100) |
|
|
(32,332) |
|
|
(59,903) |
|
|
(100,114) |
|
|